Le Lézard
Classified in: Health, Business
Subject: CSR

Fidelis Care Behavioral Health Grant Applications Now Open to Providers and Organizations Across New York State


Grants of $10,000 to $20,000 aimed at improving behavioral health outcomes, especially in underserved communities

Deadline to apply is 5 p.m. EDT May 31, 2024

LONG ISLAND CITY, N.Y., May 1, 2024 /PRNewswire/ -- In observance of Mental Health Awareness Month, Fidelis Care, a statewide health plan with more than 2.4 million members in New York State and a wholly owned subsidiary of Centene Corporation, has opened the application process for its 2024 behavioral health grant program. The grants range from $10,000 to $20,000 each and are aimed at assisting providers and community-based organizations that support behavioral health and wellness, especially in underserved communities. The application is available at fideliscare.org/BH-grants. Deadline to apply is 5 p.m. EDT May 31, 2024.  

The National Alliance on Mental Illness reports that one in five U.S. adults experience mental illness and one in six U.S. children ages 6 to 17 experience a mental health disorder each year. In addition, the Substance Abuse and Mental Health Services Administration notes that approximately 20.2 million adults age 18 or older had a substance use disorder in 2020. Access to behavioral health services, however, is often not equitable across populations. The World Health Organization says people exposed to adverse circumstances including poverty, violence, disability, and inequality are at higher risk of developing a mental health condition, underscoring the significant impact of mental illness and substance use disorder on individuals and society.

"Recognizing and addressing disparities is critical in ensuring that everyone has equal access to behavioral health support and resources," said Fidelis Care Chief Medical Officer Dr. Vincent Marchello. "These grants can help deepen Fidelis Care's relationships with providers and community-based social need service organizations to get people the help they need to live fulfilling lives."

Fidelis Care plans to announce the recipients of its 2024 behavioral health grant program awards by July 31, 2024.

About Fidelis Care 
Fidelis Care is a mission-driven health plan offering quality, affordable coverage for children and adults of all ages and at all stages of life. With more than 2.4 million members statewide, Fidelis Care believes that all New Yorkers should have access to affordable, quality health insurance. Follow us on LinkedIn at linkedin.com/company/fidelis-care, Instagram at @fideliscare, and on Facebook at facebook.com/fideliscare. For more information, call Fidelis Care at 1-888-FIDELIS (1-888-343-3547) or visit fideliscare.org.

Media Contact     
[email protected]

SOURCE Fidelis Care


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: